Aptevo Therapeutics
APVO
2 hedge funds and large institutions have $352K invested in Aptevo Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
69% less capital invested
Capital invested by funds: $1.13M → $352K (-$774K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$283K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$142K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16K |
| 4 |
EARNEST Partners
Atlanta,
Georgia
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AF
26
Allworth Financial
Folsom,
California
| $4 | – | – | – |
|
27
Citigroup
New York
| $2 | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $1 | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $1 | – | – | – |
|
|
30
EARNEST Partners
Atlanta,
Georgia
| – | -$5 | – | – |
|
|
31
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$16K | – | – |
|
APVO Hedge Fund Activity: Q4 2023 in Review
2 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2023, worth a combined $352K — down 69% from $1.13M a quarter earlier.
Fund positioning in APVO was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $142K. The largest seller was Armistice Capital, exiting entirely with an estimated $283K sold.
- 2 institutional investors held Aptevo Therapeutics (APVO) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $352K of Aptevo Therapeutics stock for Q4 2023, down 69% quarter-over-quarter.
- 1 fund opened new Aptevo Therapeutics positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest Aptevo Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $142K added.
- The largest Aptevo Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $283K sold.
Based on aggregated 13F filings for Q4 2023.